$54.80+1.37% today
AI Take · AlgoThesis
BioMarin's 29.8 P/E is strikingly elevated for a biotech firm with an RSI of 44.2, suggesting the market is pricing in substantial future growth despite moderate momentum. The 5.27% short interest is unremarkable, but the disconnect between valuation and current technical weakness is noteworthy—the stock sits below its 52-week high yet commands premium multiples typical of growth narratives. This positioning leaves little room for disappointment; any stumble in pipeline execution or guidance could trigger meaningful multiple compression. The setup appears priced for perfection with limited margin of safety.
Snapshot
Market cap
$10.4B
P/E
29.8
Forward P/E
13.0
EPS (TTM)
$1.76
Dividend yield
—
Net margin
10.8%
ROE
5.8%
RSI (14)
44
Beta
0.65
Short % of float
5.3%
Days to cover
5.4
52w high
No
Recent headlines
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect
Yahoo
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026
Yahoo
Biomarin Pharmaceutical Inc. Presents New Data on the Effect of Long-Term Treatment with VOXZOGO on Arm Span, Bone Health and Growth in Children with Achondroplasia
Finnhub
Peers in Pharmaceutical Preparations
Build a thesis around BMRN
Type a thesis in plain English. AlgoThesis researches it with real data, cites sources, and hands back a tradeable basket.
Open in AlgoThesis →